295 related articles for article (PubMed ID: 29774081)
1. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of
Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y
Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081
[No Abstract] [Full Text] [Related]
2. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
3. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
[TBL] [Abstract][Full Text] [Related]
5. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
7. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
8. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
10. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV
Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184
[TBL] [Abstract][Full Text] [Related]
11. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
[TBL] [Abstract][Full Text] [Related]
13. p53-dependent repression of polo-like kinase-1 (PLK1).
McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
[TBL] [Abstract][Full Text] [Related]
14. MiRNA-875-3p alleviates the progression of colorectal cancer via negatively regulating PLK1 level.
Li SS; Zhu HJ; Li JY; Tian LM; Lv DM
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1126-1133. PubMed ID: 32096168
[TBL] [Abstract][Full Text] [Related]
15. Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Chen Y; Fang L; Zhang J; Li G; Ma M; Li C; Lyu J; Meng QH
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282916
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.
Yu Z; Deng P; Chen Y; Liu S; Chen J; Yang Z; Chen J; Fan X; Wang P; Cai Z; Wang Y; Hu P; Lin D; Xiao R; Zou Y; Huang Y; Yu Q; Lan P; Tan J; Wu X
Adv Sci (Weinh); 2021 Dec; 8(23):e2100759. PubMed ID: 34881526
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
[TBL] [Abstract][Full Text] [Related]
19. Positive expression of basic transcription factor 3 predicts poor survival of colorectal cancer patients: possible mechanisms involved.
Liu Q; Wu J; Lu T; Fang Z; Huang Z; Lu S; Dai C; Li M
Cell Death Dis; 2019 Jul; 10(7):509. PubMed ID: 31263147
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.
Zhang J; He P; Xi Y; Geng M; Chen Y; Ding J
Oncotarget; 2015 Feb; 6(5):2917-27. PubMed ID: 25595900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
